Editorial: Innovative Strategies and New Insights for the Treatment of Stage III Non-small Cell Lung Cancer
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Bortolot M, Cortiula F, Fasola G, De Ruysscher D, Naidoo J, Hendriks L
. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials. Cancer Treat Rev. 2024; 129:102797.
DOI: 10.1016/j.ctrv.2024.102797.
View
2.
Wu Y, Dziadziuszko R, Ahn J, Barlesi F, Nishio M, Lee D
. Alectinib in Resected -Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024; 390(14):1265-1276.
DOI: 10.1056/NEJMoa2310532.
View
3.
Felip E, Altorki N, Zhou C, Vallieres E, Martinez-Marti A, Rittmeyer A
. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023; 34(10):907-919.
DOI: 10.1016/j.annonc.2023.07.001.
View
4.
Bartolomeo V, Cortiula F, Hendriks L, De Ruysscher D, Filippi A
. A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023; 118(5):1455-1460.
DOI: 10.1016/j.ijrobp.2023.11.005.
View
5.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S, Gao S
. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023; 389(6):491-503.
PMC: 11074923.
DOI: 10.1056/NEJMoa2302983.
View